These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 32983128)

  • 21. Myeloid-derived suppressor cells (MDSCs) in patients with solid tumors: considerations for granulocyte colony-stimulating factor treatment.
    Pilatova K; Bencsikova B; Demlova R; Valik D; Zdrazilova-Dubska L
    Cancer Immunol Immunother; 2018 Dec; 67(12):1919-1929. PubMed ID: 29748897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells.
    Alissafi T; Hatzioannou A; Mintzas K; Barouni RM; Banos A; Sormendi S; Polyzos A; Xilouri M; Wielockx B; Gogas H; Verginis P
    J Clin Invest; 2018 Aug; 128(9):3840-3852. PubMed ID: 29920188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Signal transducer and activator of transcription proteins: regulators of myeloid-derived suppressor cell-mediated immunosuppression in cancer.
    Ko HJ; Kim YJ
    Arch Pharm Res; 2016 Nov; 39(11):1597-1608. PubMed ID: 27572156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suppression of T cells by myeloid-derived suppressor cells in cancer.
    Chen J; Ye Y; Liu P; Yu W; Wei F; Li H; Yu J
    Hum Immunol; 2017 Feb; 78(2):113-119. PubMed ID: 27939507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Granulocyte Progenitor Stage Is a Key Target of IRF8-Mediated Regulation of Myeloid-Derived Suppressor Cell Production.
    Netherby CS; Messmer MN; Burkard-Mandel L; Colligan S; Miller A; Cortes Gomez E; Wang J; Nemeth MJ; Abrams SI
    J Immunol; 2017 May; 198(10):4129-4139. PubMed ID: 28356386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer.
    Li K; Shi H; Zhang B; Ou X; Ma Q; Chen Y; Shu P; Li D; Wang Y
    Signal Transduct Target Ther; 2021 Oct; 6(1):362. PubMed ID: 34620838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of Myeloid-Derived Suppressor Cells in Tumor Growth and Metastasis.
    Bayik D; Lee J; Lathia JD
    Exp Suppl; 2022; 113():189-217. PubMed ID: 35165865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting myeloid-derived suppressor cells for cancer immunotherapy.
    Liu Y; Wei G; Cheng WA; Dong Z; Sun H; Lee VY; Cha SC; Smith DL; Kwak LW; Qin H
    Cancer Immunol Immunother; 2018 Aug; 67(8):1181-1195. PubMed ID: 29855694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Visualization and quantification of
    Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
    Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alteration of functionality and differentiation directed by changing gene expression patterns in myeloid-derived suppressor cells (MDSCs) in tumor microenvironment and bone marrow through early to terminal phase of tumor progression.
    Mahanti K; Saha J; Sarkar D; Pramanik A; Roy Chattopadhyay N; Bhattacharyya S
    J Leukoc Biol; 2024 Apr; 115(5):958-984. PubMed ID: 38236200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Roles of the Exosomes Derived From Myeloid-Derived Suppressor Cells in Tumor Immunity and Cancer Progression.
    Chen Z; Yuan R; Hu S; Yuan W; Sun Z
    Front Immunol; 2022; 13():817942. PubMed ID: 35154134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Valproic acid attenuates immunosuppressive function of myeloid-derived suppressor cells.
    Xie Z; Ago Y; Okada N; Tachibana M
    J Pharmacol Sci; 2018 Aug; 137(4):359-365. PubMed ID: 30177294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct mechanisms govern populations of myeloid-derived suppressor cells in chronic viral infection and cancer.
    Tcyganov EN; Hanabuchi S; Hashimoto A; Campbell D; Kar G; Slidel TW; Cayatte C; Landry A; Pilataxi F; Hayes S; Dougherty B; Hicks KC; Mulgrew K; Tang CA; Hu CA; Guo W; Grivennikov S; Ali MA; Beltra JC; Wherry EJ; Nefedova Y; Gabrilovich DI
    J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34228641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myeloid-derived suppressor cells as effectors of immune suppression in cancer.
    Pyzer AR; Cole L; Rosenblatt J; Avigan DE
    Int J Cancer; 2016 Nov; 139(9):1915-26. PubMed ID: 27299510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting myeloid-derived suppressive cells in the tumor microenvironment to enhance the efficacy of cancer immunotherapy.
    Huo S; Liu L; Li Q; Wang J
    Discov Med; 2020; 30(161):119-128. PubMed ID: 33593480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
    J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells.
    Trillo-Tinoco J; Sierra RA; Mohamed E; Cao Y; de Mingo-Pulido Á; Gilvary DL; Anadon CM; Costich TL; Wei S; Flores ER; Ruffell B; Conejo-Garcia JR; Rodriguez PC
    Cancer Res; 2019 Oct; 79(19):5034-5047. PubMed ID: 31409640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives.
    Mortezaee K
    Life Sci; 2021 Jul; 277():119627. PubMed ID: 34004256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential.
    Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L
    Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MDSCs: Key Criminals of Tumor Pre-metastatic Niche Formation.
    Wang Y; Ding Y; Guo N; Wang S
    Front Immunol; 2019; 10():172. PubMed ID: 30792719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.